<bill session="115" type="h" number="5914" updated="2019-04-18T16:23:59Z">
  <state datetime="2018-05-22">REFERRED</state>
  <status>
    <introduced datetime="2018-05-22"/>
  </status>
  <introduced datetime="2018-05-22"/>
  <titles>
    <title type="official" as="introduced">To require a study and report on policy and regulatory changes that may have contributed to the opioid epidemic.</title>
    <title type="display">To require a study and report on policy and regulatory changes that may have contributed to the opioid epidemic.</title>
  </titles>
  <sponsor bioguide_id="M001187"/>
  <cosponsors/>
  <actions>
    <action datetime="2018-05-22">
      <text>Introduced in House</text>
    </action>
    <action datetime="2018-05-22" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="h" session="115" relation="unknown" number="4482"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Congressional oversight"/>
    <term name="Drug trafficking and controlled substances"/>
    <term name="Drug, alcohol, tobacco use"/>
    <term name="Government studies and investigations"/>
    <term name="Health care coverage and access"/>
    <term name="Health programs administration and funding"/>
    <term name="Prescription drugs"/>
    <term name="State and local government operations"/>
  </subjects>
  <amendments/>
  <summary date="2018-05-22T04:00:00Z" status="Introduced in House">This bill requires the Government Accountability Office to report on health care policy changes that may have contributed to the rise in opioid overdoses and deaths over the last 10 years.

The report must include an examination of:

 federal decisions relating to pain management strategies, state prescription drug monitoring programs, prescribing limitations, and pain medications with and without abuse-deterrent formulations.</summary>
  <committee-reports/>
</bill>
